Catalysts About Basilea Pharmaceutica Basilea Pharmaceutica is a Swiss biopharmaceutical company focused on anti infective medicines for serious fungal and bacterial infections. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Basilea Pharmaceutica Basilea Pharmaceutica is a Swiss anti infectives specialist focused on developing and partnering innovative antifungal and antibacterial medicines for serious hospital and community infections. What are the underlying business or industry changes driving this perspective?Read more
Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.Read more
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of antifungal for the treatment of severe invasive infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
